Lacosamid-i.v.-Register (LCM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01620840 |
Recruitment Status :
Completed
First Posted : June 15, 2012
Last Update Posted : May 28, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization | Drug: Lacosamide 10mg/ml |
Study Type : | Observational |
Actual Enrollment : | 130 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Lacosamid-i.v.-Register |
Study Start Date : | June 2011 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

Group/Cohort | Intervention/treatment |
---|---|
Lacosamid-i.v. treatment |
Drug: Lacosamide 10mg/ml
intravenous administration up to 10 days
Other Name: VimpatⓇ |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- before any data are collected for any patient in this registry an ehtical committee must be notified of the registry and written data consent must be properly executed and documented
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01620840
Germany | |
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Neurologie | |
Kiel, Schleswig-Holstein, Germany, 24105 |
Principal Investigator: | Ulrich Stephani, Prof.Dr.med. | University hospital Schleswig-Holstein, Germany |
Responsible Party: | Ulrich Stephani, Prof. Dr. med. Ulrich Stephani, University Hospital Schleswig-Holstein |
ClinicalTrials.gov Identifier: | NCT01620840 |
Other Study ID Numbers: |
UCB-LCM-2011 |
First Posted: | June 15, 2012 Key Record Dates |
Last Update Posted: | May 28, 2015 |
Last Verified: | May 2015 |
oral administration of Lacosamide is not possible or adequate |
Seizures Nervous System Diseases Neurologic Manifestations Lacosamide Anticonvulsants |
Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |